12 patients decrease with stable disease after 4 or more cycles click to follow.
– One patient with ovarian cancer an unconfirmed partial response with 62 percent decline in CA125 after cycle 2 had; – 12 patients decrease with stable disease after 4 or more cycles, including one patient with ovarian cancer, which owned a 28 percent CA125 after six cycles of treatment had.KOS-1584 was well tolerated Common toxicities were primarily gastrointestinal and fatigue One patient a dose-limiting toxicity at the highest current dose . The cohort will be expanded more experience further experience at this dose click to follow . Clinical trials. 1 clinical trial of KOS-1584 is administered every three weeks continued the the recommended Phase 2 dose. Mayo Clinic, 200 First St. SW Rochester. (more…)